← All trials
NCT07283640
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2026
- Primary completion
- Aug 31, 2029
- Completion date
- Aug 31, 2031
- First posted
- Dec 16, 2025
- Last posted
- Dec 22, 2025
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- AmgenCollaborator
- University of Texas at HoustonOfficial
- Syndax PharmaceuticalsCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.